#Shanghai #USA #Pulnovo Medical #PADN #Hipertensión Pulmonar

Pulnovo Medical's PADN-HF-PH Trial Results

On September 3, 2026, during the prestigious ESC congress, Pulnovo Medical announced significant findings from its innovative PADN-HF-PH trial, showcasing its commitment to advancing treatments for heart disease. The findings were also published in the renowned New England Journal of Medicine (NEJM).

Key Trial Outcomes

The trial involved 264 patients with pulmonary hypertension associated with left heart disease (PH-LHD) and yielded remarkable results:

• - A 51% reduction in the risk of clinical worsening was observed in patients receiving the Pulmonary Artery Denervation (PADN) alongside guideline-directed medical therapy (GDMT) compared to those receiving only GDMT.
• - The annualized rate of clinical worsening was dramatically lowered, highlighting PADN's potential to alter the disease landscape rather than merely delaying symptoms.
• - Improvements in functional capacity were noted, with a net increase of 24.8 meters in the 6-minute walk test after 12 months, reflecting enhanced patient mobility and quality of life.

This clinical trial stands as a landmark achievement in the field of cardiovascular interventions, offering vital insights into effective therapies for PH-LHD.

Trial Design and Significance

The PADN-HF-PH trial is a multicenter, randomized controlled study designed to assess the safety and efficacy of adding PADN to GDMT. It emphasizes the urgent need to address the complexities of treating patients where pulmonary hypertension exacerbates left heart conditions. This is particularly pressing since existing treatments primarily focus on tackling the underlying cardiac issues rather than the pulmonary hypertension itself.

The study reveals that the integration of PADN offers comprehensive management in reducing the burden of disease and enhancing overall patient prognoses.

Clinical Framework and Future Implications

The findings highlight the critical need for new treatment paradigms in managing PH-LHD, potentially guiding future standardized therapies. As seen in clinical settings, patients with PH-LHD often suffer compounded symptoms due to the interaction between pulmonary hypertension and left heart disease. This trial elucidates a new method to break this cycle of worsening health outcomes.

Comprehensive Clinical Improvements

The benefits of the PADN procedure extend beyond mere statistical measurements:

• - Patients reported significant improvements in their health-related quality of life, as demonstrated by lower levels of NT-proBNP, a biomarker indicative of heart failure.
• - The safety profile was reassuring, with adverse effects limited primarily to minor access site hematomas, underscoring PADN's tolerability.

The need for specialized therapies addressing the root causes of PH-LHD has never been more evident. The evidence generated from the PADN-HF-PH study propels forward the understanding of treatment needs and potential solutions for patients suffering from this condition.

Conclusion

Pulnovo Medical's PADN technology—recognized internationally in treatment guidelines—may herald a new era in the management of pulmonary hypertension. By addressing the hyperactivation of the sympathetic nervous system, this minimally invasive therapy can potentially revolutionize the way healthcare providers treat heart and lung diseases concurrently.

As the landscape evolves, Pulnovo Medical is dedicated to furthering its research, with ongoing trials expanding into various subtypes of pulmonary hypertension, aimed at meeting broader clinical need. The results from the PADN-HF-PH trial not only affirm the promise of this innovative approach but also prioritize patient outcomes in cardiovascular care, aligning with the broader mission of enhancing global health standards.